Global Non-Alcoholic Steatohepatitis Market Size and Forecast 2024-2033|AstraZeneca PLC, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited

The Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Non-Alcoholic Steatohepatitis Treatment Market:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

According to The Business Research Company’s Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024, The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The growth in the historic period can be attributed to rising prevalence of nash, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine.. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.

An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in March 2023, according to a report published by the Office for Health Improvement and Disparities, a UK government department, the number of premature deaths from liver disease witnessed a 3.7% increase, totaling 10,501 in 2021. Among these fatalities, 5,686 were attributed to alcohol-related liver disease in England, while non-alcoholic fatty liver disease accounted for 320 premature deaths. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

The development of the non-alcoholic steatohepatitis (NASH) drug is a key trend gaining popularity in the non-alcoholic steatohepatitis treatment market. Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as; ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

The non-alcoholic steatohepatitis treatment market report table of contents includes:

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics

3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Treatment Market – Macro Economic Scenario

5. Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth

26. South America Non-Alcoholic Steatohepatitis Treatment Market

27. Brazil Non-Alcoholic Steatohepatitis Treatment Market

28. Middle East Non-Alcoholic Steatohepatitis Treatment Market

29. Africa Non-Alcoholic Steatohepatitis Treatment Market

30. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Company Profiles

Top Major Players: